This inventor holds 2 USPTO granted patents. Top assignees: Tokai Pharmaceuticals, Inc., University of Washington, University System of Maryland. Active years: 2016-2017.
Company Filing History:
2 out of 6 
2 out of 2,166 
2 out of 2,023 
Years Active: 2016-2017
Title: Karen Ferrante: Innovator in Cancer Treatment
Introduction
Karen Ferrante is a prominent inventor based in Boston, MA, known for her significant contributions to the field of cancer treatment. With a focus on neoplastic disorders, she has developed innovative methods that aim to improve patient outcomes in prostate cancer therapy. Her work has led to the filing of two patents, showcasing her dedication to advancing medical science.
Latest Patents
Karen Ferrante's latest patents include groundbreaking methods and compositions for the treatment of prostate cancer. These patents specifically address castration-resistant and androgen receptor antagonist-resistant prostate cancer. The methods involve administering a CYP17-lyase inhibitor of Formula II, which has the potential to enhance treatment efficacy for patients in need.
Career Highlights
Throughout her career, Karen has worked with notable organizations such as Tokai Pharmaceuticals, Inc. and the University of Washington. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to significant advancements in cancer research.
Collaborations
Karen has collaborated with esteemed colleagues, including Vincent C. O. Njar and Amina Zoubeidi. These partnerships have further enriched her research and development efforts, leading to innovative solutions in cancer treatment.
Conclusion
Karen Ferrante's work exemplifies the impact of innovation in the medical field, particularly in the treatment of prostate cancer. Her patents and collaborations highlight her commitment to improving patient care through scientific advancements.